Our Pipeline

We are advancing a pipeline of Affibody^® radioligand therapies (RLTs) to realize the breakthrough potential of this highly targeted, personalized, and precise form of cancer treatment across a broad range of solid tumors. Our Affibody^® RLT candidates in development represent cancer types that have been previously inaccessible to conventional RLT technologies, and we are focused on bringing this powerful cancer-fighting drug modality to more cancer patients.

Affibody^® targeting moieties are uniquely suited for radiotherapy applications. Leveraging this platform, we are developing a pipeline of novel RLTs directed against well-validated targets in solid tumors. Our lead program, ABY-271, is a HER2-targeted Affibody^® conjugated to 177Lu, being developed for the treatment of metastatic breast cancer.

Our pipeline also includes partnership programs in immunology.